A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women with Inflammatory Bowel Disease study is being conducted at the University of California San Francisco and 30 other sites around the United States who are part of the CCFA Clinical Alliance. The aim of this study is to determine the effect of medication use and disease activity on the outcome of pregnancy among women with IBD up to 18 years from birth.
Female patients with confirmed IBD diagnoses who are pregnant and taking immunosuppressants and/or biologic therapy
Pregnant female patients younger than 18 years of age
Confirmed multiple gestation
Female patients with confirmed IBD diagnoses who are pregnant
Other
Prospective
Not listed
Determine whether children born to women with IBD have higher rates of developmental delay compared to their age matched non-IBD peers, as measured by the Ages and Stages Questionnaire (ASQ-3) at ages 12, 24, 36, and 48 months
Determine whether the rate of any adverse pregnancy outcomes in a prospective national sample of women from the United States with IBD differ with respect to exposure to azathioprine/6MP or anti-TNF therapy
Determine whether breastfeeding impacts developmental delay, growth and infectious complications in children born to women with IBD
Click on the lead sponsor to view all of their trials.
University of California, San Francisco
Lead sponsor
Crohn's and Colitis Foundation
Collaborator
